Brexit could delay cancer drugs by up to two years

British patients could wait longer to access new cancer drugs if it leaves the European Union as planned, a former head of the drug regulatory agency has warned. In an interview with the BBC’s Today Programme the former chair of the Medicines and Healthcare Products Regulatory Agency, Alasdair Breckenridge, said drug companies may need to ...

Already a member?

Login to keep reading.

© 2021 the limbic